Barbara Anthony

Why are health care costs rising every year in Massachusetts?

/0 Comments/in , , , /by Barbara Anthony and Joshua Archambault
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

This op-ed originally appeared in The Boston Globe.

The largest driver is the increase in prices by health systems that have the clout to command higher payments and work to recruit more patients to their high-cost facilities.

By Josh Archambault and Barbara Anthony

Can you afford a new car every year? Massachusetts families now pay about $21,000 a year — more than the average cost of a new compact car — in health insurance premiums every year. And that doesn’t include out-of-pocket expenses before insurance kicks in. As a result, middle-class families are spending a record more than 30 percent of their budgets on health care.

Why are health care costs rising every year?

The largest driver is the increase in prices by health systems that have the clout to command higher payments and work to recruit more patients to their high-cost facilities. Unsurprisingly, recent proposals from Mass General Brigham (MGB, formerly Partners HealthCare) and Boston Children’s Hospital, two of the most expensive regional systems, to further expand their footprints outside of Boston have triggered controversy.

Both MGB and Children’s have a long history of charging significantly more for the same services than other hospitals. Both also have a history of buying up physician practices, raising prices, and directing patients into their high-cost facilities.

In 2014 the courts blocked Partners’ plan to expand through the acquisition of rivals. Now MGB appears determined to achieve its goals by constructing new capacity in suburban areas near lower-priced competitors.

MGB and Children’s have submitted paperwork to the state’s Determination of Need program, which determines whether the Commonwealth will grant a permission slip to open, expand, or renovate a facility.

For years, supporters have argued that DON regulations contain health care costs. That is a questionable claim given that a recent Health Policy Commission report highlighting that costs have exceeded the state’s benchmark for growth in the last two years.

A 2021 compact car costs roughly the same as the same model in 2001, and it is now packed with new safety features and technology. During that same period, average family insurance costs have tripled from $7,000 to over $21,000. The quality of outcomes is uneven, and prices vary wildly based on your insurance plan and provider.

A relatively small section of MGB’s plan, related to a proposed expansion of its ambulatory care presence in Westborough, Westwood, Woburn, and in New Hampshire, has garnered great attention. Of the 1,000 comments Massachusetts’ Department of Public Health received, 850 relate to these settings.

A close look at MGB’s massive $2.3 billion proposal shows, however, that 90 percent of the spending is on renovations and expansions at or around its Boston facilities, which sometimes charge rates three times higher than what Medicare pays. Oddly, there is little if any opposition to this grand proposal. So much for the DON process cutting costs.

No doubt, the much smaller MGB expansion into the suburbs has drawn significant political and business opposition.

Less expensive rivals, often community hospitals, fear that MGB will siphon off well-insured patients and potentially put them out of business. In a truly competitive market, less expensive providers that produce similar outcomes will prove to be more attractive to patients. However, our current health care market is anything but competitive, as is evidenced by the fact that the high-priced systems have cut special deals with the major insurers to pay them more.

The DON procedure is expensive, time-consuming, and opaque. New market entrants, who could provide competition and lower prices, lack the financial and political resources that big existing providers have, so seldom do they dare navigate the DON process. Regulators sit as judge and juror as proponents submit consultant reports and cost estimates to bolster their case, and existing providers lobby against their would-be competitors. Patients, who are not considered parties of record, have limited ability to comment on any of the “independent” consultant reports.

Because of potential conflicts of interest, several members of the Public Health Council, the body that will vote on the MGB proposals, are expected to recuse themselves.

The state Department of Public Health and the Health Policy Commission must take a hard look at the impact of these proposals. For far too long, Massachusetts has struggled to tame ever-escalating health care costs.

Determination of Need evaluations may not be a topic at Massachusetts dinner tables, but the state’s decisions will dictate how much money remains in residents’ paychecks, and where and when we receive care. These latest proposals are shining a spotlight on the DON procedure; if it fails to deliver on lowering costs, the process will highlight the need for reform.

Josh Archambault and Barbara Anthony are senior fellows at the Pioneer Institute.

Get Updates On Our Healthcare Cost Transparency Initiative!

Related Posts:

Is this PBM tactic blocking healthcare access?

Utilization Management (UM) was originally a strategy designed to improve the safety, quality, and cost-effectiveness of physician prescribing. However, UM has grown exponentially over the last decade, becoming more a tactic for Pharmacy Benefit Managers (PBMs) to manage costs to benefit their bottom line.

Drug Price Control: Bad Medicine for Healthcare and Region

Hubwonk host Joe Selvaggi talks with Dr. Bill Smith, Director of Pioneer Institute’s Life Sciences Initiative, about the impact of the Inflation Reduction Act on long-term health costs. They discuss the bill's unintended consequences, potential effect on the region’s vibrant pharmaceutical research and development sector, and what citizens can do about it.

The Realities Behind US Healthcare Spending

Healthcare policy is an all-encompassing term. It plays a role in every individual’s life; how it is curated, developed, and maintained has a significant long-term impact on the quality of life of any given community. It is critical that policymakers consistently adapt and amend healthcare policies in the ever-changing global pricing and affordability environment while providing funding support for optimal quality of care.

Healthcare dominates the job market.

0 Comments
/
Healthcare and social assistance are among the most important…

Drug Cost Disruption: Direct Generic Access Can Save Consumers Billions

Hubwonk host Joe Selvaggi talks with Dr. Hussain Lalani about his recently published research on the potential for more than $3 billion in savings were Medicare to use Mark Cuban’s new direct-to-consumer drug company to purchase generics.
This file is licensed under the Creative Commons Attribution 2.0 Generic license.

Healthcare Employs More on Cape Cod Than Any Other Sector

0 Comments
/
Despite being a major tourist destination, the largest employment sector on Cape Cod is not related to tourism: it is healthcare!

Doctors With Borders: Curing Shortages With International Lifeline

This week on Hubwonk, host Joe Selvaggi talks with Cicero Institute’s Jonathan Wolfson about the growing doctor shortage and the potential to alleviate the crisis by tapping the global supply of well-trained physicians eager to find safety and freedom in the US.

Pharmacy Benefit Profiteers: Distortions and Costs of Half-Trillion Dollar Drug Middlemen

Hubwonk Host Joe Selvaggi talks with ALVA10 Chief Executive Hannah Mamuszka and Dr. Blake Long about the perverse incentives imposed by Pharmacy Benefit Managers adding nearly $500 billion to U.S. drug costs.

Exploiting Charity Drugs: Hospital Program Earns Billions But Forgets Mission

Hubwonk host Joe Selvaggi talks with Pioneer Institute’s Dr. Bill Smith about his recently released paper entitled, "340B Drug Discounts, An Increasingly Dysfunctional Federal Program," which analyzes the evolution of a well-intentioned program to offer discounted drugs to the uninsured from a benefit that had helped charitable hospitals to one that has exploded to generate billions in profits while serving fewer uninsured.

Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes

Over the past decade, the revenue for hospitals generated by the federal 340B drug discount program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide, according to a new study published by Pioneer Institute. The Pioneer Institute study, “340B Drug Discounts: An Increasingly Dysfunctional Program,” notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.